Aptadir Therapeutics raises $45M Seed to silence the genes behind rare disease

Aptadir Therapeutics (Milan) has raised $45 million in a Seed round (approximately €40 million), led by 4BIO Capital, the London-based venture firm focused on life sciences. The round, one of the largest early-stage funding rounds by an Italian health startup, will fund the company's preclinical drug development pipeline targeting rare genetic diseases and underserved cancers.

A novel class of RNA inhibitors

Aptadir is developing what it calls directional RNA inhibitors — a class of RNA-based molecules designed to silence genes that contribute to disease. The scientific approach draws on research in RNA and DNA biology, genetic disorders, leukaemia, and immunotherapeutics by an international team of scientists.

The company's initial clinical focus is Fragile X Syndrome, a genetic condition caused by the silencing of the FMR1 gene and the most common inherited cause of intellectual disability and developmental delays. There are no approved disease-modifying treatments for Fragile X despite decades of research, which both defines the market opportunity and signals the scientific difficulty. Aptadir's platform is also being directed at underserved cancers where defective gene silencing plays a central role.

The round was co-invested by Extend, Italy's national technology transfer hub for biotechnology and pharmaceuticals, which backed Aptadir at pre-seed — a continuity signal from the institution most familiar with the company's early scientific trajectory. Additional investors include CDP Venture Capital, XGEN Venture, and CE-Ventures.

The case for a large Seed

A $45 million Seed at the preclinical stage warrants scrutiny. The rationale is platform breadth: Aptadir is not developing a single drug for a single condition; it is building a toolbox for a class of gene pathways previously considered undruggable. If the directional RNA inhibitor mechanism proves generalisable, the Fragile X program becomes proof-of-concept for a portfolio, not just a single asset.

The company positions this as a platform with pipeline potential across conditions where a gene has been pathologically silenced. 4BIO Capital, whose portfolio includes companies developing gene therapies and molecular medicines at comparable preclinical stages, has the institutional context to calibrate what that claim is worth and what it will cost to test it.

Capital from the round will fund advancement of the DiR pipeline through preclinical and into early clinical stages.